Program of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicenter, randomized controlled study (PRIZE) sub study

Conditions

The analysis data set of the main trial will be used as the database of this study.

Saito Y, Tanaka A, Ishizu T, Yoshida H, Kubota Y, Nanasato M, Matsuhisa M, Ohya Y, Kobayashi Y, Node K, PRIZE Study Investigators.

2023-07-051 citations

10.1038/s41598-023-37183-0

PS-C04-6: ASSOCIATION BETWEEN SERUM URATE LEVEL AND CAROTID ATHEROSCLEROSIS: AN INSIGHT FROM A POST-HOC ANALYSIS OF THE RANDOMIZED CLINICAL TRIAL (PRIZE)

Atsushi Tanaka, Koichi Node

Journal of Hypertension2023-01-01

10.1097/01.hjh.0000914616.81997.6c

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study

Yuichi Saito, Atsushi Tanaka, Yuji Koide, Hisako Yoshida, Daigaku Uchida et al. (10 authors)

RMD Open2022-09-011 citations

10.1136/rmdopen-2022-002505

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial

Atsushi Tanaka, Shigeru Toyoda, Toru Kato, Hisako Yoshida, Shuichi Hamasaki et al. (10 authors)

RMD Open2022-04-018 citations

10.1136/rmdopen-2022-002226

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The analysis data set of the main trial will be used as the database of this study. Number of cases in the database: Febuxostat group: 239 cases Control group: 244 cases

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Rate of change from baseline after 24 months in the mean IMT value of the common carotid artery determined by carotid artery ultrasound	—

Secondary

Measure	Time frame
1. IMT, FMD, PWV, CAVI, EF, LVEF, E, A, TRPG, e' and E/e' by treatment group at each measurement point 2. Blood test values (red blood cells, white blood cells, hemoglobin, hematocrit, blood platelet count, AST, ALT, LDH, BUN, Na, K, Cl, blood glucose, serum uric acid level, serum lipids: TC, HDL-C, TG, non-HDL-C, LDL-C, serum creatinine, eGFR), serum biomarker values NT-proBNP, high-sensitivity CRP, 1, 5AG, small dense LDL, RLP-C, MDA-LDL, serum cystatin C, RAGE, high-molecular adiponectin, high-sensitivity troponin I, ANGPTL2, Alb, Ca, FGF23, P), and urine test values (urinary albumin excretion, urinary L-FABP) by treatment group at each measurement point	—

Measure

Time frame

1. IMT, FMD, PWV, CAVI, EF, LVEF, E, A, TRPG, e' and E/e' by treatment group at each measurement point 2. Blood test values (red blood cells, white blood cells, hemoglobin, hematocrit, blood platelet count, AST, ALT, LDH, BUN, Na, K, Cl, blood glucose, serum uric acid level, serum lipids: TC, HDL-C, TG, non-HDL-C, LDL-C, serum creatinine, eGFR), serum biomarker values NT-proBNP, high-sensitivity CRP, 1, 5AG, small dense LDL, RLP-C, MDA-LDL, serum cystatin C, RAGE, high-molecular adiponectin, high-sensitivity troponin I, ANGPTL2, Alb, Ca, FGF23, P), and urine test values (urinary albumin excretion, urinary L-FABP) by treatment group at each measurement point

—

Countries

Japan

Contacts

Public ContactAtsushi Tanaka

Saga University Department of Cardiovascular Medicine

cardiostudy@ml.cc.saga-u.ac.jp0952-34-2364

Outcome results